Sustained beneficial metabolic effects 18 months after a 30-day very low calorie diet in severely obese, insulin-treated patients with type 2 diabetes

2007 ◽  
Vol 77 (1) ◽  
pp. 70-76 ◽  
Author(s):  
Ingrid M. Jazet ◽  
Anton J. de Craen ◽  
Eveline M. van Schie ◽  
A. Edo Meinders
Diabetes Care ◽  
2004 ◽  
Vol 27 (2) ◽  
pp. 348-353 ◽  
Author(s):  
S. M. Willi ◽  
K. Martin ◽  
F. M. Datko ◽  
B. P. Brant

2018 ◽  
Vol 27 (1) ◽  
pp. 210-217.e3 ◽  
Author(s):  
Rachel J. Perry ◽  
Liang Peng ◽  
Gary W. Cline ◽  
Yongliang Wang ◽  
Aviva Rabin-Court ◽  
...  

2009 ◽  
Vol 161 (3) ◽  
pp. 397-404 ◽  
Author(s):  
Ivana Dostálová ◽  
Tomáš Roubíček ◽  
Markéta Bártlová ◽  
Miloš Mráz ◽  
Zdena Lacinová ◽  
...  

ObjectiveMacrophage inhibitory cytokine-1 (MIC-1) is a novel regulator of energy homeostasis. We explored whether alterations in MIC-1 levels contribute to metabolic disturbances in patients with obesity and/or obesity and type 2 diabetes mellitus (T2DM).DesignWe measured serum MIC-1 levels and its mRNA expression in subcutaneous and visceral adipose tissue of 17 obese nondiabetic women, 14 obese women with T2DM and 23 healthy lean women. We also explored the relationship of MIC-1 with anthropometric and biochemical parameters and studied the influence of 2-week very low calorie diet (VLCD) on serum MIC-1 levels.MethodsSerum MIC-1 levels were measured by ELISA and its mRNA expression was determined by RT-PCR.ResultsBoth obese and T2DM group had significantly elevated serum MIC-1 levels relative to controls. T2DM group had significantly higher serum MIC-1 levels relative to obese group. Serum MIC-1 positively correlated with body weight, body fat, and serum levels of triglycerides, glucose, HbAlc, and C-reactive protein and it was inversely related to serum high-density lipoprotein cholesterol. Fat mRNA MIC-1 expression did not significantly differ between lean and obese women but it was significantly higher in subcutaneous than in visceral fat in both groups. VLCD significantly increased serum MIC-1 levels in obese but not T2DM group.ConclusionElevated MIC-1 levels in patients with obesity are further increased by the presence of T2DM. We suggest that in contrast to patients with cancer cachexia, increased MIC-1 levels in obese patients and diabetic patients do not induce weight loss.


2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Amna Ali Shaghouli ◽  
Rola Aranky

Abstract Introduction Type 2 diabetes (T2D) has been defined as a lifelong condition which is inevitably progressive.1 The idea that beta cell function certainly declines with time in diabetic people who have developed T2D has been definitively disproven.2 It has been recognised that the processes that cause T2D can be reversed and T2D remission can be achieved.2 Many studies show that, by changing life style dramatically, controlling diabetes can improve significantly and a significant proportion of patients can also reduce or come off their glucose-lowering therapies.3 This has been formally proven in DIRECT, with clear evidence of gradual continuing improvement in beta cell functional capacity over at least 12 months.4 Remission was linked to weight loss, as two third of those who lost more than 10kg were in remission after two years.4 Methods A case study was done on a 66 years old male, who is diabetic for the last 12 years, with other comorbidities: hypertension and hypercholesterolemia. He presented with Hemoglobin A1C (HbA1c) of 7.4% with BMI of 37.7 kg/m2 on four oral hypoglycaemic agents and basal insulin of 20 units per day. His treatment was changed by adding Glucagon-like peptide-1 receptor agonists (GLP-1 RA) for better glycemic control and weight reduction in a setting of a multidisciplinary team approach, including endocrinologist, diabetes educator, dietitian and physical trainer. Results Over the last one year and two months, patient was able to stop all his diabetes medication including GLP-1 RA. Over three years follow ups patient achieved weight reduction of 17.3% with HbA1c of 6.5% and additional other metabolic factor benefits. Conclusion Even with 12 years of diabetes, reversibility of T2D can still be achieved with weight reduction of over 15%. We will wait for another 10 months to reconfirm our data for two years remission. References 1. Steven S, Taylor R. Restoring normoglycaemia by use of a very low calorie diet in long-and short-duration Type 2 diabetes. Diabetic Medicine. 2015 Sep;32(9):1149-55. 2. Nagi D, Hambling C, Taylor R. Remission of type 2 diabetes: a position statement from the Association of British Clinical Diabetologists (ABCD) and the Primary Care Diabetes Society (PCDS). British Journal of Diabetes. 2019 Jun 27;19(1):73-6. 3. Wing RR, Blair E, Marcus M, Epstein LH, Harvey J. Year-long weight loss treatment for obese patients with type II diabetes: does including an intermittent very-low-calorie diet improve outcome?. The American journal of medicine. 1994 Oct 1;97(4):354-62. 4. Taylor R, Al-Mrabeh A, Zhyzhneuskaya S, Peters C, Barnes AC, Aribisala BS, Hollingsworth KG, Mathers JC, Sattar N, Lean ME. Remission of human type 2 diabetes requires decrease in liver and pancreas fat content but is dependent upon capacity for β cell recovery. Cell metabolism. 2018 Oct 2;28(4):547-56.


PLoS ONE ◽  
2014 ◽  
Vol 9 (11) ◽  
pp. e112835 ◽  
Author(s):  
Maria A. Sleddering ◽  
Albert J. Markvoort ◽  
Harish K. Dharuri ◽  
Skhandhan Jeyakar ◽  
Marieke Snel ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document